A Decadal Bibliometric Analysis of Circulating Tumor DNA (ctDNA) Research in Lung Cancer (2012-2022).
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: lung cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] This study provides a comprehensive quantitative synthesis of the ctDNA landscape in lung cancer over the past decade. By identifying key research hotspots and evolutionary trends, our findings offer valuable insights for clinicians and researchers, highlighting the transition of ctDNA from experimental validation to critical translational applications in precision oncology.
[BACKGROUND] Recent studies have demonstrated that the plasma level of circulating tumor DNA (ctDNA) has emerged as a highly effective, minimally invasive biomarker in patients with lung cancer.
- 표본수 (n) 237
APA
Zhang X, Bai J (2026). A Decadal Bibliometric Analysis of Circulating Tumor DNA (ctDNA) Research in Lung Cancer (2012-2022).. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. https://doi.org/10.1007/s12094-026-04285-w
MLA
Zhang X, et al.. "A Decadal Bibliometric Analysis of Circulating Tumor DNA (ctDNA) Research in Lung Cancer (2012-2022).." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026.
PMID
41741796 ↗
Abstract 한글 요약
[BACKGROUND] Recent studies have demonstrated that the plasma level of circulating tumor DNA (ctDNA) has emerged as a highly effective, minimally invasive biomarker in patients with lung cancer. This study aimed to perform bibliometric analysis to systematically evaluate the development trends of ctDNA in lung cancer for future research.
[METHODS] All articles on the role of ctDNA for detecting lung cancer from January 1, 2012, to December 31, 2022, were retrieved from the Web of Science (WoS) Core Collection database. Data analyses were performed using the R package Bibliometrix, VOS viewer 1.6.18, and online analysis in WoS.
[RESULTS] A total of 1122 publications were retrieved: 807 primary articles and 315 review articles. The annual publication volume exhibited a significant upward trajectory, with a Compound Annual Growth Rate (CAGR) of 48.3%. China had the highest article output (379 papers), whereas the citation rate of papers from the United States was the highest (20,239 citations). The journal "Cancers" had the highest number of publications. Wang J was the most prolific author (35 papers), whereas Diehn M was the most cited author (4460 citations). The five most frequent keywords were "lung cancer" (n = 237), "plasma" (n = 227), "acquired-resistance" (n = 207), "circulating tumor DNA" (n = 177), and "gefitinib" (n = 151).
[CONCLUSION] This study provides a comprehensive quantitative synthesis of the ctDNA landscape in lung cancer over the past decade. By identifying key research hotspots and evolutionary trends, our findings offer valuable insights for clinicians and researchers, highlighting the transition of ctDNA from experimental validation to critical translational applications in precision oncology.
[METHODS] All articles on the role of ctDNA for detecting lung cancer from January 1, 2012, to December 31, 2022, were retrieved from the Web of Science (WoS) Core Collection database. Data analyses were performed using the R package Bibliometrix, VOS viewer 1.6.18, and online analysis in WoS.
[RESULTS] A total of 1122 publications were retrieved: 807 primary articles and 315 review articles. The annual publication volume exhibited a significant upward trajectory, with a Compound Annual Growth Rate (CAGR) of 48.3%. China had the highest article output (379 papers), whereas the citation rate of papers from the United States was the highest (20,239 citations). The journal "Cancers" had the highest number of publications. Wang J was the most prolific author (35 papers), whereas Diehn M was the most cited author (4460 citations). The five most frequent keywords were "lung cancer" (n = 237), "plasma" (n = 227), "acquired-resistance" (n = 207), "circulating tumor DNA" (n = 177), and "gefitinib" (n = 151).
[CONCLUSION] This study provides a comprehensive quantitative synthesis of the ctDNA landscape in lung cancer over the past decade. By identifying key research hotspots and evolutionary trends, our findings offer valuable insights for clinicians and researchers, highlighting the transition of ctDNA from experimental validation to critical translational applications in precision oncology.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Effects of varicocele and microsurgical varicocelectomy on the metabolites in semen.
- Novel staurosporine-type indolocarbazole glycoalkaloids as potent and selective FLT3-ITD inhibitors for acute myeloid leukemia.
- IDH1 mutation creates a dependency on fatty acid metabolism that underlies sensitivity to cuproptosis in acute myeloid leukemia cells.
- MASH and liver fibrosis: Clinical trials to watch.
- E3 ubiquitin ligase DTX3L promotes breast cancer progression by enhancing PKCα ubiquitination and inhibiting the p38 MAPK signaling pathway.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection.
- From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.
- Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
- From feasibility to translational pathways: a bibliometric and knowledge-mapping analysis of urine-based liquid biopsy in urologic cancers (2015-2025).
- A subset of MMR-proficient colon cancers responds to neoadjuvant immunotherapy.